The Effects of SGLTi on Diabetic Cardiomyopathy
The Effects of SGLTi on Diabetic Cardiomyopathy
Diabetic cardiomyopathy is associated with significant morbidity and mortality. It is
 considered as a cardiac muscle disorder secondary to diabetes mellitus (DM). Certain studies
 show the clinical benefit of SGLT-s inhibitors on reducing cardiovascular outcomes amongst
 patients with type II DM that go beyond the correction of hyperglycemic perse. Thus an
 observational imaging study is proposed to identify mechanistic insights of the drug group
 over cardiovascular events.
Diabetic cardiomyopathy is defined as ventricular dysfunction in diabetic patients in the
 absence of coronary artery disease and hypertension. It is considered as a cardiac muscle
 disorder due to the metabolic consequences of DM characterized by left ventricular
 hypertrophy, left ventricular diastolic dysfunction (in the early stage), and/or systolic
 dysfunction. To date, there is no specific treatment proven effective for the condition due
 to the incomplete understanding of the pathogenesis.

 Recent studies however prove the efficacy of SGLT-2 inhibitors on reducing the primary
 composite end point of cardiovascular outcomes including hospitalization for heart failure,
 cardiovascular death, and all-cause death amongst patients with type II DM. Such clinical
 benefit is apparently mainly stemmed from the reduction in heart failure related mortality
 and sudden cardiac death rather than the macro-vascular events such as myocardial infarct and
 stroke, suggesting addition benefits going beyond the correction of hyperglycemia perse.
 These studies thus raise the possibility that the drug may have direct effects on the
 myocardium that conferring the clinical benefit not related the modification of traditional
 risk factors such as glycemic control, lipid, blood pressure, and obesity.

 A single-arm, observational cardiac magnetic resonance imaging study is proposed in type II
 diabetic patients before and 2 months after initiation of dapagliflozin. The aim is to
 identify mechanistic insights leading to the unexpected clinical benefit of SGLT inhibition.
Inclusion Criteria:

 -  type 2 diabetes

 -  40-90 years old

 -  HbA1c >= 6.5%

 -  history of heart failure with reduced ejection fraction

 -  indications for SGLT inhibition on clinical ground

 Exclusion Criteria:

 -  angina pectoris or chest discomfort

 -  prior coronary artery bypass grafts

 -  coronary artery stenting within 6 months of study enrolment

 -  pervious myocardial infarct

 -  any contraindication for stress CMR testing

 -  renal impairment with eGFR <45ml/min/1.73m2

 -  limited life expectancy <5 years, for example due to pulmonary disease, cancer or

 -  significant hepatic failure

 -  contraindication to dapagliflozin or other SGLT2 inhibitors

 -  unable to take dapagliflozin

 -  patients currently on and SGLT2 inhibitor

 -  planned need for concomitant cardiac surgery or coronary intervention

 -  refusal or inability to sign an informed consent

 -  potential for on-compliance towards the requirements in the trial protocol (especially
 the medical treatment) or follow-up visits